Distribution of study events according to both actual event and observed event (by linkage).

<p>Distribution of study events according to both actual event and observed event (by linkage).</p

The effect of changing sensitivity and specificity on observed incidence when true incidence is 1.0%, 5.0% and 20.0%.

<p>The effect of changing sensitivity and specificity on observed incidence when true incidence is 1.0%, 5.0% and 20.0%.</p

Distribution of prisoner vital status on the basis of record linkage and known vital status.

<p>Distribution of prisoner vital status on the basis of record linkage and known vital status.</p

10(Framingham Equation) categories by treatment arm at baseline and 48 weeks.

<p>10(Framingham Equation) categories by treatment arm at baseline and 48 weeks.</p

Baseline predictors of change in limb fat mass over 48

<p>Baseline predictors of change in limb fat mass over 48</p

Baseline Characteristics.

<p>Baseline Characteristics.</p

Patient disposition of SECONDLINE body composition sub-study.

<p>Patient disposition of SECONDLINE body composition sub-study.</p

The distribution of percent limb fat gain by treatment arm.

<p>The distribution of percent limb fat gain by treatment arm.</p

Mean change in limb fat mass from week

<p>Mean change in limb fat mass from week</p

Virologic response at Week 96, by randomised arm, study population and screening strata.

<p>RAL = lopinavir/ritonavir+raltegravir Control = lopinavir/ritonavir+2/3 nucleoside/nucleotide reverse transcriptase inhibitors. *grey circle = screening plasma viral load strata, P interaction = 0.81, bars are 95%confidence intervals (CI).</p